Trial Profile
A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Fotemustine; Nivolumab
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms NIBIT-M2
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 24 Oct 2023 Results (As of May 1, 2023, n=80; 7-year outcomes) assessing efficacy of Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases presented at the 48th European Society for Medical Oncology Congress
- 10 Jun 2021 Results of an interim analysis published in the Clinical Cancer Research